The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases

Trends in Pharmacological Sciences

Volumn 24, Issue 9, 2003, Pages 471-478

  Cai, Hua ^a   Griendling, Kathy K ^a   Harrison, David G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOCYNIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOREDUCTASE INHIBITOR; PICRORHIZA KURROA EXTRACT; PROTEIN; PROTEIN GP91; PROTEIN P47; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S 17834; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HYPERTENSION; HYPERTROPHY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR TISSUE;

EID: 0042379916     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00233-5     Document Type: Review

References (85)

1. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:2000;840-844.
2. McCord J.M. The evolution of free radicals and oxidative stress. Am. J. Med. 108:2000;652-659.
3. Thomson L., et al. Kinetics of cytochrome c2+ oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch. Biochem. Biophys. 319:1995;491-497.
4. Rubbo H. Nitric oxide and peroxynitrite in lipid peroxidation. Medicina (B Aires). 58:1998;361-366.
5. Abu-Soud H.M., Hazen S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem. 275:2000;37524-37532.
6. Griendling K.K., et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20:2000;2175-2183.
7. Babior B.M. The respiratory burst oxidase. Curr. Opin. Hematol. 2:1995;55-60.
8. Groemping Y., et al. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 113:2003;343-355.
9. Griendling K.K., et al. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86:2000;494-501.
10. Touyz R.M., et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90:2002;1205-1213.
11. Wassmann S., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22:2002;300-305.
12. Pagano P.J., et al. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14483-14488.
13. Suh Y.A., et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:1999;79-82.
14. Cheng G., et al. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 269:2001;131-140.
15. 2+-activated NADPH oxidase in testis, spleen, and lymph nodes. J. Biol. Chem. 276:2001;37594-37601.
16. Lambeth J.D. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. Curr. Opin. Hematol. 9:2002;11-17.
17. Gorlach A., et al. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res. 87:2000;26-32.
18. Sorescu D., et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation. 105:2002;1429-1435.
19. Rey F.E., et al. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox). Circulation. 106:2002;2497-2502.
20. Banfi B., et al. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J. Biol. Chem. 278:2003;3510-3513.
21. Geiszt M., et al. Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J. Biol. Chem. 278:2003;20006-20012.
22. Takeya R., et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J. Biol. Chem. 278:2003;25234-25246.
23. Miura H., et al. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ. Res. 92:2003;e31-e40.
24. Ushio-Fukai M., et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 91:2002;1160-1167.
25. Lavoie J.L., Sigmund C.D. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology. 144:2003;2179-2183.
26. Griendling K.K., et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1994;1141-1148.
27. Touyz R.M., et al. c-Src induces phosphorylation and translocation of p47phox. role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23:2003;981-987.
28. Touyz R.M., Schiffrin E.L. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension. 34:1999;976-982.
29. Seshiah P.N., et al. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 91:2002;406-413.
30. Lavigne M.C., et al. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation. 104:2001;79-84.
31. Landmesser U., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 40:2002;511-515.
32. Li J.M., Shah A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II: Role of the p47phox subunit. J. Biol. Chem. 278:2003;12094-12100.
33. Fukui T., et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ. Res. 80:1997;45-51.
34. Wingler K., et al. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic. Biol. Med. 31:2001;1456-1464.
35. Mollnau H., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90:2002;E58-E65.
36. Fukui T., et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ. Res. 80:1997;45-51.
37. Servant M.J., et al. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J. Biol. Chem. 271:1996;16047-16052.
38. Tummala P.E., et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100:1999;1223-1229.
39. Chen X.L., et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 83:1998;952-959.
40. Schieffer B., et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ. Res. 87:2000;1195-1201.
41. Ushio-Fukai M., et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 91:2002;1160-1167.
42. Ushio-Fukai M., et al. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:2001;489-495.
43. Gorlach A., et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ. Res. 89:2001;47-54.
44. Page E.L., et al. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J. Biol. Chem. 277:2002;48403-48409.
45. Brandes R.P., et al. The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic. Biol. Med. 32:2002;1116-1122.
46. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90:2002;251-262.
47. Grote K., et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ. Res. 92:2003;e80-e86.
48. Cai H., et al. Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol. Pharmacol. 63:2003;325-331.
49. Cai H., et al. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J. Biol. Chem. 277:2002;48311-48317.
50. Saito S., et al. Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertens. Res. 19:1996;201-206.
51. Pueyo M.E., et al. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am. J. Physiol. 274:1998;C214-C220.
52. Thorup C., et al. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries. J. Am. Soc. Nephrol. 10:(Suppl. 11):1999;S220-S224.
53. Rajagopalan S., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97:1996;1916-1923.
54. Wang H.D., et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ. Res. 88:2001;947-953.
55. Laursen J.B., et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 95:1997;588-593.
56. Zalba G., et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension. 35:2000;1055-1061.
57. Landmesser U., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111:2003;1201-1209.
58. Warnholtz A., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 99:1999;2027-2033.
59. Barry-Lane P.A., et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J. Clin. Invest. 108:2001;1513-1522.
60. Hsich E., et al. Vascular effects following homozygous disruption of p47(phox): An essential component of NADPH oxidase. Circulation. 101:2000;1234-1236.
61. Kirk E.A., et al. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 20:2000;1529-1535.
62. Guzik T.J., et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 86:2000;E85-E90.
63. Hink U., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88:2001;E14-E22.
64. Kim Y.K., et al. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes. 51:2002;522-527.
65. Bauersachs J., et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 100:1999;292-298.
66. Li J.M., et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 40:2002;477-484.
67. Kurz S., et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation. 99:1999;3181-3187.
68. Suh Y.A., et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:1999;79-82.
69. Yang S., et al. A new superoxide-generating oxidase in murine osteoclasts. J. Biol. Chem. 276:2001;5452-5458.
70. Shimohama S., et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:2000;5-9.
71. Shi J., et al. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47phox. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6014-6018.
72. Ikeda Y., et al. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc. Res. 49:2001;69-77.
73. Chan Y.R., et al. Anti-microbial activity and cell binding are controlled by sequence determinants in the anti-microbial peptide PR-39. J. Invest. Dermatol. 116:2001;230-235.
74. Tanaka K., et al. PI3-kinase p85alpha is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells. Jpn. J. Cancer Res. 92:2001;959-967.
75. Lopes N.H., et al. Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. Circ. Res. 91:2002;798-805.
76. Jacobson G.M., et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ. Res. 92:2003;637-643.
77. Rey F.E., et al. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 89:2001;408-414.
78. Engels F., et al. Effects of apocynin, a drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism. FEBS Lett. 305:1992;254-256.
79. Stolk J., et al. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 11:1994;95-102.
80. Beswick R.A., et al. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 38:2001;1107-1111.
81. Engels F., et al. Effects of apocynin, a drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism. FEBS Lett. 305:1992;254-256.
82. Lapperre T.S., et al. Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Lett. 443:1999;235-239.
83. Diatchuk V., et al. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J. Biol. Chem. 272:1997;13292-13301.
84. Cayatte A.J., et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NAD(P)H oxidase. Arterioscler. Thromb. Vasc. Biol. 21:2001;1577-1584.
85. Vecchione C., Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91:2002;173-179.